USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note C - Fair Value Measures (Tables)

Note C - Fair Value Measures (Tables)

6 Months Ended

Jul. 02, 2022

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

				*Fair Value Measurements Using*
	*July 2,*			*Inputs*
	*2022*			*Level 1*		*Level 2*		*Level 3*
Money market funds included in cash equivalents	$	160,287		$	160,287	$	—	$	—
Foreign currency contracts included in prepaid expenses and other current assets		1,435			—		1,435		—
Contingent consideration included in other current liabilities of ($338) and other long-term liabilities of ($548)		(886	)		—		—		(886	)
	$	160,836		$	160,287	$	1,435	$	(886	)

				*Fair Value Measurements Using*
	*January 1,*			*Inputs*
	*2022*			*Level 1*		*Level 2*			*Level 3*
Money market funds included in cash equivalents	$	163,619		$	163,619	$	—		$	—
Foreign currency contracts included in other current liabilities		(461	)		—		(461	)		—
	$	163,158		$	163,619	$	(461	)	$	—

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details